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ABSTRACT 
 
Rationale: Endothelial-to-mesenchymal transition (EndMT) is a dynamic biological process involved in 
pathological vascular remodelling. However, the molecular mechanisms that govern this transition remain 
largely unknown, including the contribution of long non-coding RNAs (lncRNAs).  
 
Objectives: To investigate the role of lncRNAs in EndMT and their relevance to vascular remodelling.  
 
Methods and Results: To study EndMT in vitro, primary endothelial cells (EC) were treated with 
transforming growth factor-β2 and interleukin-1β. Single-cell and bulk RNA-sequencing were performed 
to investigate the transcriptional architecture of EndMT and identify regulated lncRNAs. The functional 
contribution of seven lncRNAs during EndMT was investigated based on a DsiRNA screening assay. The 
loss of lncRNA MIR503HG was identified as a common signature across multiple human EC types 
undergoing EndMT in vitro. MIR503HG depletion induced a spontaneous EndMT phenotype, while its 
overexpression repressed hallmark EndMT changes, regulating 29% of its transcriptome signature. 
Importantly, the phenotypic changes induced by MIR503HG were independent of miR-424 and miR-503, 
which overlap the lncRNA locus. The pathological relevance of MIR503HG down-regulation was 
confirmed in vivo using Sugen/Hypoxia (SuHx)-induced pulmonary hypertension (PH) in mouse, as well 
as in human clinical samples, in lung sections and blood outgrowth endothelial cells (BOECs) from 
pulmonary arterial hypertension (PAH) patients. Overexpression of human MIR503HG in SuHx mice led 
to reduced mesenchymal marker expression, suggesting MIR503HG therapeutic potential. We also 
revealed that MIR503HG interacts with the Polypyrimidine Tract Binding Protein 1 (PTB1) and regulates 
its protein level. PTBP1 regulation of EndMT markers suggests that the role of MIR503HG in EndMT 
might be mediated in part by PTBP1.  
 
Conclusions: This study reports a novel lncRNA transcriptional profile associated with EndMT and reveals 
the crucial role of the loss of MIR503HG in EndMT and its relevance to pulmonary hypertension.  
 
Keywords:  
Endothelium, endothelial-to-mesenchymal transition, EndMT, lncRNA, miRNA, endothelial cell, 
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Nonstandard Abbreviations and Acronyms: 
 
BOEC: blood outgrowth endothelial cells 
EC: Endothelial cell 
EndMT: Endothelial to mesenchymal transition 
GO: Gene ontology 
HUVEC: Human umbilical vein endothelial cells  
HPAEC:  Human pulmonary artery endothelial cells 
IL-1β: interleukin-1β 
LncRNA: long non-coding RNA 
MiRNA/Mi-R: MicroRNA 
PAH: Pulmonary arterial hypertension 
PH: Pulmonary hypertension 
(sc)RNA-seq: (Single-Cell) RNA sequencing 
SuHx: Sugen Hypoxia PH mouse model 






Endothelial to mesenchymal transition (EndMT) is a complex cellular transdifferentiation process 
whereby endothelial cells (EC) lose their endothelial identity and acquire mesenchymal cell characteristics1. 
Akin to epithelial-to-mesenchymal transition, EndMT has been described during heart embryonic 
development1, as well as in neovascularization and tissue repair2. While its role remains under debate, 
EndMT has been shown to be involved in a variety of maladaptive tissue remodelling scenarios3-6 such as 
atherosclerosis7, and vein graft remodelling8.  Such remodelling is also causal in pulmonary arterial 
hypertension (PAH), a progressive disease with limited treatment options, largely defined by structural 
alterations to the lung vasculature. These alterations include stiffening of proximal pulmonary arteries, 
increased intimal and medial arterial thickness, along with the eventual development of complex neointimal 
lesions. Underlying many of these changes is the increased deposition of extracellular matrix and 
appearance of smooth muscle-like cells with high proliferative and migratory potential9. Several reports 
now suggest the involvement of EndMT during both the development and progression of PAH, opening 
new therapeutic avenues10-12. As both PAH and EndMT are linked with imbalance in TGF- signaling, 
several in vitro models have been developed relying on TGF- signaling as the main inducer of EndMT, 
alone or with an additional stimulus7, 13.    
 
EndMT is characterised by the decrease of endothelial markers such as PECAM1/CD31 and VE-
Cadherin (CDH5) in association with the gain of mesenchymal markers such as α-smooth muscle actin 
(ACTA2), calponin (CNN1)1, as well as enhanced collagen production. EndMT is also associated with 
increased expression of several transcription factors such as TWIST, SMAD3, SNAI1 and SNAI21. 
However, the precise molecular mechanisms and upstream determinants governing this transition, remain 
to be rigorously defined, particularly when considering vascular heterogeneity and the presence of distinct 
stages of EndMT. Indeed, cells that have lost EC markers and thus undergone a complete EndMT process 
showed high proliferative and migratory capacity whereas partial EndMT cells, still expressing EC markers, 
have also been isolated12.  While both protein-coding genes and miRNAs have been widely involved in 
EndMT regulation1, 14, the role of long non-coding RNAs (lncRNAs) is yet to be thoroughly explored. 
LncRNAs are long (>200nt) non-coding transcripts, often expressed at low levels but with high specificity. 
Several lncRNAs have been described as critical regulators of gene expression both at the transcriptional 
and post-transcriptional level and have roles in a wide range of diseases15. LncRNAs have already been 
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adenocarcinoma transcript 1) has been implicated in the modulation of TGF-β1-induced EndMT through 
regulation of the miR-145-TGFBR2/SMAD3 axis17. Recently, the lncRNA GATA6-AS (antisense transcript 
of GATA6) was shown to suppress TGF-β2-induced EndMT in vitro via targeting LOXL2 (Lysyl oxidase 
homolog 2)18.  
 
Here, we have applied an unbiased approach using single-cell and bulk RNA sequencing of an in 
vitro model of EndMT to characterise EndMT transcriptional changes. We identified 103 differentially 
expressed lncRNAs during EndMT progression in both venous and arterial ECs. Among these lncRNAs, 
the substantive loss of the lncRNA MIR503HG was a consistent molecular event during EndMT, both in 
vitro and in vivo mouse and human samples. We further showed a direct contribution of MIR503HG on the 







The authors declare that all methods, material list and processed experimental data are available within the 
article and its online files. Any additional data are available from the corresponding author upon request. 
Raw and processed sequencing data are available at GEO database (accession: GSE118446, GSE118815, 
GSE159843). All methods are included in the Online Supplemental Materials. Please see the Major 






Induction of EndMT in arterial and venous ECs using TGF-2 and IL-1.  
 
To replicate EndMT in vitro and characterise its molecular signature, human primary venous 
(HUVEC) and arterial (HPAEC) endothelial cells were subjected to a combination of transforming growth 
factor beta 2 (TGF-β2) and interleukin 1 beta (IL-1β) for 7 days13. RT-qPCR analysis confirmed EndMT 
induction in TGF-β2 and IL-1β co-treated cells, but not TGF-β2 or IL-1β alone, with the loss of the 
endothelial marker PECAM1, gain of mesenchymal markers ACTA2 and COL1A1 and the EndMT-
associated transcription factor SNAI2 (Figure 1A and Online Figure I_A). In addition, changes to PECAM1 
and SNAI2 expression were confirmed at the protein level by immunofluorescence microscopy (Figure 1B 
and Online Figure I_B). We also confirmed the decrease of PECAM1 and increase of ACTA2 protein levels 
by Western blot in HPAEC (Online Figure I_C). We also assessed the effect of the TGF-β2 and IL-1β co-
treatment on the proliferative and migratory capacities of HUVEC and observed a significant decrease of 
cellular proliferation (Figure 1D) but no significant change in the migratory capacity of EndMT cells 
(Figure 1E).  
 
Together, these results confirm the induction of an EndMT-like profile in both arterial and venous 
EC using a TGF-β2 and IL-1β co-treatment model. 
 
Transcriptional profiling of primary ECs undergoing EndMT. 
 
To characterise EndMT transitioning populations and transcriptomic changes associated with this 
transition, we carried out single-cell RNA sequencing (scRNA-seq) on co-treated and control HUVEC at 
day 0, day 3 and day 7 using 10X Genomics technology. Based on tSNE dimensionality reduction, we 
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day 3 and day 7 untreated cells showed some overlap, day 7 treated cells clustered separately from day 3 
treated cells showing a time-dependent effect of the treatment (Figure 2A). The loss of an endothelial 
signature was confirmed using PECAM1, CDH5, ICAM2, ERG and VWF, and the gain of a 
mesenchymal/EndMT signature using TAGLN, COL1A1, and S100A4 and SNAI2 expression (Figure 2B). 
Eleven clusters were identified (Figure 2C), with clusters 1-6 corresponding to control HUVEC and 
displaying an endothelial transcriptional program, whereas clusters 7-11 from co-treated HUVEC displayed 
a downregulation of endothelial genes and progression to a mesenchymal signature (Figure 2D). In 
agreement with the decrease of proliferation described above (Figure 1D), we observed a decrease of MKI67 
expression in groups 8-11 (Figure 2D). Cluster 11, composed exclusively from day 7 co-treated HUVEC, 
constituted a new ‘advanced EndMT’ population (Figure 2D). Cluster 11 was characterised by the 
expression of 132 marker genes, including known EndMT markers (TGFR1, NOTCH2 and BMP2) and 
novel genes involved in cell differentiation (ANKRD1, OSGIN2) and stress signaling (CXCL8 and CSF3) 
(Online Figure II_A-B).   
 
To identify the complete transcriptomic changes associated with EndMT, including lncRNAs, we 
performed high-depth bulk RNA-sequencing of HUVEC and HPAEC undergoing EndMT after 7 days 
(Figure 2, Online Figure III_A). Principal component analysis (PCA) confirmed a clear segregation of the 
different treatment groups, compared to untreated controls (Figure 2E, Online Figure III_B). HUVEC and 
HPAEC derived EndMT-cells clustered separately from their respective control group, but also from each 
other, suggesting transcriptional heterogeneity in the induction of EndMT across vascular beds (Figure 2E, 
Online Figure III_B). We identified 1721 up-regulated and 1260 down-regulated genes in EndMT-HUVEC 
compared to untreated cells (Online Dataset I), with 46% of the up-regulated and 60% of the down-
regulated genes not observed in the single-treatment groups (Figure 2F, Online Figure III_C-D). 
Importantly, around 40% of regulated genes in HUVECs were also affected in HPAEC (Figure 2F-G and 
Online Dataset I). Gene Ontology (GO) analysis found that up-regulated genes associated with immune 
response, while down-regulated genes associated with GO terms related to DNA conformation and cell 
cycle (Online Figure III_E and Online Dataset II).  
 
LncRNA expression was affected upon EndMT induction, with 69 lncRNAs up-regulated and 34 
down-regulated in HUVEC and HPAEC (Online Dataset I). Top lncRNA candidates were selected based 
on fold change, level of expression and genomic location: MIR503HG, HOTAIRM1, AC123023.1, CTC-
378H22.1, LINC00702, MIR3142HG, RP11-37B2.1, AC147651.4 and RP11-79H23.3 (Figure 2H and 
Online Figure IV_A-B). Differential expression patterns were confirmed by RT-qPCR in HUVEC and 
HPAEC (Online Figure IV_C-D) for all candidate lncRNAs except CTC-378H22.1 and HOTAIRM1, which 
failed validation and were removed from downstream analysis (Online Figure IV_A-B). Using the single-
cell RNA-seq dataset, we confirmed the expression changes of all candidates in the ‘advanced’ EndMT 
population (Figure 2I). Interestingly, the change for some candidates, including MIR503HG, was also 
observed in the day 3 sample clusters (Figure 2I) suggesting a role in the early phase of the transition.     
 
Screening for lncRNA function during EndMT. 
 
A siRNA-mediated knockdown approach was utilised to screen the functional contribution of each 
lncRNA to EndMT (Online Figure V) based on the expression of defined EndMT markers (i.e. PECAM1, 
ACTA2, SNAI2, COL1A1). Significant knockdowns were confirmed for four lncRNAs but not for 
LINC00702, AC147651.4 and AC123023.1, which were subsequently eliminated from this study (Online 
Figure V_A). Targeted depletion of the selected lncRNA candidates lead to significant changes in EndMT 
markers, highlighting their potential causal contribution to EndMT (Online Figure V_B). Notably, 
knockdown of MIR503HG induced a robust EndMT profile, even in the absence of TGF-β2 and IL-1β co-
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Loss of MIR503HG is a common feature of EndMT in vitro. 
 
MIR503HG is an intergenic lncRNA located on chromosome X with five reported isoforms on 
GENCODE.v26 (Figure 3A and Online Figure VI_A). While RNA-seq data showed a significant down-
regulation of all isoforms (Online Figure VI_B), we confirmed the down-regulation of the top three 
expressed isoforms 2, 3 and 5 by RT-qPCR following EndMT induction in HUVEC (Online Figure VI_B-
C). Importantly, as the MIR503HG gene locus overlaps with the miR-424 and miR-503 genes (Figure 3A), 
we analysed their expression during EndMT and observed a significant down-regulation of both miR-424-
5p and miR-503-5p (Figure 3B).    
 
Interestingly, the final 595 base-pair region of isoform 2 (MIR503HG_2) is highly conserved based 
on PhyloP score (Online Figure VI_A), as was its secondary substructure19. As such, we chose 
MIR503HG_2 as our main transcript of interest. In addition to HUVEC and HPAEC (online Figure IV_C-
D), down-regulation of MIR503HG_2 after TGF-2 and IL-1 co-stimulation was also seen in Human 
Saphenous Vein Endothelial Cells (HSVEC) and Human Coronary Artery Endothelial Cells (HCAEC) 
(Figure 3C). Additionally, MIR503HG_2 expression was decreased in a second in vitro model of EndMT 
using TGF-2 and H2O2 co-stimulation7 (Figure 3D). Using our single-cell RNA-seq data, we also 
confirmed the positive correlation of MIR503HG with the EC signature and a negative correlation for 
mesenchymal signature (Figure 3E). 
 
As subcellular localisation of lncRNA can provide information regarding function, MIR503HG 
localisation was determined by RT-qPCR of nuclear/cytoplasmic fraction (Figure 3F) and RNA-FISH 
(Figure 3G) in HUVEC. Together, this data revealed that MIR503HG is predominantly localised to the 
nucleus, with a mean of 2.16 copies per nuclei (Figure 3G).  
 
Loss of MIR503HG initiates EndMT in the absence of TGF-2 and IL-1
 
           The siRNA screening approach was validated on a larger sample size. We confirmed that all 
expressed MIR503HG isoforms were down-regulated in the si503HG samples (Online Figure VII_A) and 
that, in the absence of treatment, si503HG induces an EndMT profile based on RT-qPCR analysis (Figure 
4A-B). These effects were mirrored at the protein level based on immunofluorescence (Figure 4C) and 
western blot (Online VII_B). Furthermore, we showed that MIR503HG depletion replicated the key 
phenotypes of the EndMT model, such as loss of EC monolayer integrity (Figure 4C), decreased 
proliferation (Online Figure VII_C) but also showed a decrease of cell migration (Online Figure VII_D). 
Given the nuclear localisation of MIR503HG, an antisense GapmeR (gap503HG) was also used to 
manipulate MIR503HG expression (Online Figure VIII_A) and replicated the findings of the siRNA-
mediated knockdown, inducing similar expression changes to EndMT markers at the RNA (Online Figure 
VIII_B) and protein levels (Online Figure VIII_C).  
 
We observed a significant reduction in the expression of miR-424 and miR-503 with siRNA but not 
GapmeR-mediated MIR503HG depletion (Online Figure IX), presumably due to the oligonucleotides 
targeting the miRNA precursor. To target specifically MIR503HG, we used a lentiviral CRISPR/Cas9 gene 
editing system to delete the conserved exon of MIR503HG locus without disturbing the miRNA cluster 
upstream. Co-transduction of HUVEC using two separate lentiviral CRISPR/Cas9 guide RNA (gRNA) 
pairs, led to a >50% reduction in the expression of the target region (exon 3) (Figure 4D) while maintaining 
miR-424 and miR-503 as well as MIR503HG exon 1 expression after 8 days (Figure 4D-E). As with our 
previous knockdown strategies, reduced MIR503HG availability in HUVEC resulted in similar changes to 
EndMT marker expression (Figure 4F). Of note, for one of the guide combinations, no statistical difference 
was observed for PECAM1 and SNAI2 expression. Finally, an anti-miR strategy was used to interrogate the 
direct contribution of miR-503 and miR-424 to EndMT in HUVEC. Knocking down either miR-424 or miR-
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Moreover, EndMT was not induced by knockdown of either miRNA, with no statistical difference in 
endothelial or mesenchymal markers observed (Online Figure X_C). These data showed that the role of 
MIR503HG on EndMT regulation is independent of miR-424 and miR-503. 
 
Overexpression of MIR503HG isoform 2 represses EndMT. 
 
To assess if MIR503HG overexpression could prevent EndMT, we designed a lentiviral vector 
carrying the MIR503HG_2 transcript sequence (LNT_503HG). HUVEC were transfected with 
LNT_503HG or LNT_CT (lentivirus control). At 3 days post transduction, LNT_503HG samples showed 
an increase of MIR503HG_2 only and not isoforms 3 and 5, when compared to LNT_CT (Online Figure 
XI_A). Cellular fractionation and RNA-FISH confirmed the predominant nuclear localization of 
overexpressed MIR503HG, with a mean number of 6.46 copies per nuclei (Online Figure XI_B-D). 
Overexpression of MIR503HG (Figure 5A) did not affect expression of endothelial or mesenchymal 
markers under control conditions (Figure 5B). However, under EndMT conditions, MIR503HG 
overexpressing cells (Figure 5A) showed an increase in PECAM1 expression, and a marked suppression of 
SNAI2 and COL1A1 expression compared to LNT_CT (Figure 5B). Immunofluorescence validated these 
results at the protein level (Figure 5C).  Overexpression of MIR503HG did not affect miR-424 or miR-503 
levels compared to LNT_CT, in either control or EndMT-conditions (Online Figure XII), further 
confirming a miRNA-independent role of MIR503HG on EndMT.  
 
To identify the contribution of MIR503HG overexpression on the EndMT transcriptomic changes, 
we performed RNA-seq on control and EndMT HUVEC with lentiviral overexpression (Online Dataset 
III). PCA revealed that LNT_503HG_2 had no major effect on the transcriptome of untreated cells 
(Control_LNT_503HG_2), clustering with Control and Control_LNT_CT cells (Online Figure XIII). 
Interestingly, EndMT_LNT_503HG cells clustered in between Control and EndMT cells (Online Figure 
XIII), suggesting the treatment with LNT_503HG is preventing the EndMT process. We identified 803 and 
880 genes up- and down-regulated, respectively, by MIR503HG overexpression in EndMT 
(EndMT_LNT_503HG compared to EndMT_LNT_CT) (Figure 5D). We found a 29% overlap between 
EndMT regulated genes and the genes regulated by LNT_503 in treated conditions (Figure 5E). These 
overlapping genes include additional markers of EndMT such as the endothelial genes NR2F2 and NOS3 
as well as the mesenchymal genes TAGLN, FN1 and CNN1. This data again confirms the strong contribution 
of MIR503HG to EndMT. 
 
MIR503HG expression is lost during vascular remodelling in a mouse PH model. 
 
To examine the contribution of MIR503HG in vivo, we used a Sugen/Hypoxia (SuHx) PH mouse 
model, in which vessel remodelling involves EndMT10 (Figure 6A). Additionally, we used an inducible 
endothelial lineage tracing system of Ind.Endotrack (Cdh5-CreERT2-TdTomato) mice20, 21, in which 
TdTomato is constitutively expressed after Tamoxifen treatment in all EC regardless of subsequent changes 
in cellular phenotype8. Ind.Endotrack mice were subjected to SuHx or control conditions for 3 weeks. 
TdTomato+ cells isolated from SuHx lungs presented an EndMT profile with increased expression of 
mesenchymal-specific markers (Acta2, Vimentin and Col1a1, Snai2) and loss of endothelial specificity 
(Pecam1 and Cdh5) when compared to control mice (Figure 6B). Notably, expression of the MIR503HG 
mouse homolog, Gm28730 (locus and primers shown in Online Figure XIV), was found to be significantly 
reduced in SuHx TdTomato+ EC (Figure 6C).  
 
To establish the role of MIR503HG in EndMT in vivo, we overexpressed the human MIR503HG_2 
transcript in mice and assessed its impact on the EndMT markers after PH induction. We optimised the 
uptake of a GFP lentiviral construct on normoxic mice, using intranasal delivery. Flow cytometry analysis 
confirmed the presence of GFP+ cells in the lung, 13.7% of which corresponded to CD31+ endothelial cells 
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to 10-week-old C57BL/6 mice, which then underwent PH induction by SuHx (Figure 6D). Endothelial 
(CD31+) and CD31- lung cells were isolated by flow cytometry (Online Figure XV_B) and the expression 
of MIR503HG and EndMT markers was assessed. Human MIR503HG_2 expression was up-regulated in 
both CD31- and CD31+ lung cells for LNT_503HG mice compared to LNT_CT (Figure 6E and Online 
Figure XVI_A). The mouse MIR503HG homolog was also increased in LNT_503HG versus LNT_CT 
CD31+ ECs (Figure 6E).  Importantly, analysis of EndMT markers revealed the significant down-regulation 
of the mesenchymal markers Acta2 and Col1a1 in LNT_503HG versus LNT_CT CD31+ ECs but not in 
CD31- cells (Figure 6F and Online Figure XVI_B).  
 
These experiments show that the down-regulation of MIR503HG mouse homolog Gm28730 in PH 
is associated with EndMT and that human MIR503HG_2 overexpression can prevent the induction of 
mesenchymal markers in the lung endothelial compartment in response to EndMT-inducing stimuli in vivo. 
 
Loss of MIR503HG is associated with EndMT in Human PAH. 
 
Blood outgrowth ECs (BOECs) derived from PAH patients have been shown to recapitulate 
pulmonary endothelial cell dysfunction22. Based on the expression of endothelial and mesenchymal 
markers, we showed that BOECs derived from PAH patients presented an EndMT-like phenotype 
compared to cells from control patients that was accompanied by a significant reduction of MIR503HG_3 
and MIR503HG_5 expression (Figure 7A). 
 
To determine the association between the loss of MIR503HG and vascular remodelling, we 
analysed lung tissue sections from three PAH patients and three control lungs, using in situ hybridisation. 
In control lungs, MIR503HG expression was present throughout the vasculature (Figure 7B-C, Online 
Figure XVII_A-B and Online Figure XVIII_A). Conversely, in PAH lung vasculature, MIR503HG 
expression was detected in non-remodelled vessels but was absent from remodelled arterial vessels (Figure 
7B-C, Online Figure XVII_C-D and VXIII). 
 
Together, this demonstrated that loss of MIR503HG is observed in PAH patients in association with 
vascular remodelling. 
 
MIR503HG regulation of EndMT is mediated in part by PTBP1. 
 
To study the MIR503HG mechanism of action, we performed an RNA pulldown assay using in 
vitro synthesized biotinylated MIR503HG_2 transcripts, which were captured on streptavidin beads and 
incubated with HUVEC extracts depleted from the cytosolic fraction (Figure 8A and online Figure XIX_A-
B). Proteomic analysis by mass spectrometry (MS) was used to identify 125 significantly enriched proteins 
bound to biotinylated MIR503HG_2 compared to an eGFP RNA control (Online Dataset IV). The top two 
enriched proteins (ranked based on fold change over control) were the RNA splicing regulatory protein 
Polypyrimidine tract-binding protein 1 (PTBP1) and the heterogeneous nuclear ribonucleoprotein A0 
(HNRNPA0) (Figure 8B). Interaction of MIR503HG_2 with either PTBP1 or HNRNPA0 was validated by 
reciprocal RNA immunoprecipitation (RIP). MIR503HG_2 RNA showed a high and significant enrichment 
for PTBP1 and HNRNPA0 pulldown compared to an IgG control pulldown, while, in comparison, UBC 
mRNA showed a lower enrichment (Figure 8C). 
 
To understand the consequences of MIR503HG interaction with PTBP1 and HNRNPA0 proteins, 
we analysed PTBP1 and HNRNPA0 protein levels in MIR503HG knockdown samples. Upon MIR503HG 
depletion, we observed a significant down-regulation of PTBP1 (Figure 8D) and HNRNPA0 (online Figure 
XIX_C). Similarly, PTBP1 protein down-regulation also occurs in EndMT (Figure 8E), along with 
HNRNPA0 (online Figure XIX_D). To determine if PTBP1 or HNRNPA0 down-regulation contribute to 
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XIX_E-F) and assessed EndMT markers after 7 days. Interestingly, PTBP1 depletion led to a significant 
decrease of PECAM1 as well as the up-regulation of COL1A1 and ACTA2, although SNAI2 was unaffected 
(Figure 8F), without significantly affecting MIR503HG levels (Online Figure XIX_G-H). In contrast, 
HNRNPA0 depletion only led to a significant increase of ACTA2 (Figure 8F). Furthermore, we mined 
publicly available RNA-seq datasets from PTBP1 knockdown in HepG2 cells, a liver hepatocellular 
carcinoma with epithelial cell morphology, and compared the differentially expressed genes with LNT503 
regulated genes. This revealed a significant overlap between genes negatively regulated by MIR503HG and 
PTBP1 (online Figure XX), with 79 genes also up-regulated during EndMT (Figure 8G). Of interest, the 
overlapping genes include several known mesenchymal markers: TAGLN, COL1A1, CNN1, VCAN and 
MYL9. Altogether, these data suggest that the induction of EndMT by MIR503HG depletion may be 






With the involvement of EndMT in pathological vascular remodelling11, 23, 24, the in-depth 
characterisation of this process and its therapeutical targeting seems crucial. Here, we report the 
transcriptomic profile of primary EC undergoing EndMT in vitro using single-cell and bulk RNA-seq. We 
provide evidence of lncRNA expression changes associated with EndMT and the effect of the depletion of 
four candidate lncRNAs on EndMT. We have shown that loss of the lncRNA MIR503HG is pivotal to the 
induction of EndMT, both in vitro and in vivo, by a mechanism of action independent of miR-424 and miR-
503. MIR503HG overexpression in PAH mice affects mesenchymal marker expression, highlighting 
potential for therapeutic intervention. Furthermore, MIR503HG loss was associated with human PAH, 
further confirming its clinical relevance. Our data revealed the interaction of MIR503HG with the RNA 
binding protein PTBP1 and suggests PTBP1 protein regulation by MIR503HG contributes to EndMT. A 
graphical summary of this mechanism is shown in Figure 8H.  
 
EndMT has been observed in diseases affecting different vascular beds, from PAH23, 24 to  
atherosclerosis25 and vein graft remodelling8, 12. While context specific regulations of EndMT likely occur, 
common markers and pathways have been described1. Our data showing a large overlap of transcriptional 
changes between HUVEC and HPAEC undergoing EndMT support some common mechanisms, which 
could be targeted as a therapeutic strategy across diseases. Our work on MIR503HG revealed its relevance 
to EndMT in several EC types, two in vitro EndMT models, in a mouse model of PH and in human PAH 
samples.  
 
We propose that the TGF-β2 and IL-1β co-treatment model replicates an early stage of EndMT, as 
co-treated ECs still express the endothelial marker PECAM1 after 7 days, despite a significant down-
regulation of its expression. At this time point, we showed a decrease of cell proliferation and no statistical 
change in migration. While fully transitioned cells have increased proliferative and migratory capacity12, 
this might not be the case for transitioning cells. Indeed, decreased proliferation has been observed in 
another in-vitro EndMT model7, 10 and similar phenotypes have been described previously in primary ECs 
upon activation of the TGF-β pathway26. Further work is required to characterise the different stages of 
EndMT, in terms of gene expression as well as cell phenotypic properties, both in vitro and in vivo.  
 
MIR503HG was initially described as a hypoxia sensitive lncRNA in EC27 and several studies have 
independently focused on its role in cancer. While MIR503HG generally inhibits cell proliferation, invasion 
and migration in cancer cells 19, 28-31, except in lymphoma32, silencing of MIR503HG in ECs has been shown 
to decrease proliferation and migration27, corroborating our findings. These observations highlight the cell 
type specific effect of lncRNA modulation. Our study is the first to provide evidence for the involvement 
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Our study provides mechanistic data on MIR503HG, identifying binding partners in HUVEC. 
MIR503HG interaction with PTBP1 and HNRNPA0 was confirmed by reciprocal RNA 
immunoprecipitation. Several lncRNAs have been shown to interact with PTBP1, regulating its role in 
transcription33, splicing34 or RNA stability35. PTBP1 protein level was decreased in MIR503HG knockdown 
conditions and EndMT, suggesting MIR503HG interaction with PTBP1 in HUVEC may promote its 
stability. Knockdown of PTBP1 in HUVEC and HepG2 cells led to the upregulation of mesenchymal 
markers, showing PTBP1 plays a role in maintaining cell identity. The interaction of MIR503HG with 
HNRNPA2B1, observed in hepatocellular carcinoma31, was not detected in the HUVEC pulldown, 
suggesting cell type specific mechanism of MIR503HG. Collectively, we propose that the role of 
MIR503HG in EndMT is mediated in part by its regulation of PTBP1 protein level.   
 
Although miR-424 and miR-503 have roles in epithelial-to-mesenchymal transition36, 37, our data 
shows that MIR503HG modulation but not miRNA modulation, has an effect on the EndMT process. 
Indeed, CRISPR/Cas9 mediated deletion of the MIR503HG locus as well as MIR503HG transcript 
overexpression was sufficient to regulate EndMT, without affecting either miRNA expression.  Crucially, 
targeted depletion of miR-503 or miR-424 did not show a statistical difference in the expression of EndMT 
markers. A decrease of miR-503 and miR-424 during EndMT or upon siRNA mediated-MIR503HG 
depletion is likely due to the overlap between the miRNA precursor and MIR503HG and their potential 
transcriptional co-regulation. Whilst many miRNA host lncRNAs have been described, for the large part 
their function as independent lncRNAs, instead of pri-miRNAs, have not been determined, with the 
exception of MIR205HG/LEADeR38 and MIR100HG39.  LEADeR lncRNA is produced through splicing of 
the MIR205HG locus and regulates differentiation of human prostate basal cells independently of miR-205 
function38, while MIR100HG regulates cell cycle through its interaction with the RNA binding protein 
HuR39. Our data provide another example of miRNA host gene with a long non-coding RNA role, 
highlighting the need to dissociate the effect of host genes from their overlapping miRNAs. 
 
Our study also shows a clear correlation between loss of MIR503HG and the gain of EndMT 
markers, using a mouse model of PH and human BOECs. In PAH lung tissues, we showed the association 
between MIR503HG loss and vessel remodelling. Despite the semi-quantitative analysis of the in-situ 
hybridisation presented, further in-depth studies are required to accurately establish a link between 
MIR503HG transcript levels and the extent of remodelling seen in PAH, as well as the contribution of 
EndMT in the context of human disease. Indeed, recent studies suggested the large contribution of smooth 
muscle cells and pericytes in the remodelling and lesions observed in PAH40, 41, ultimately highlighting the 
multifactorial nature of the disease. It will also be of interest to assess if MIR503HG down-regulation is 
relevant in other vascular remodelling pathologies associated with EndMT, such as atherosclerosis and vein 
graft failure. 
 
Our data, showing a decrease of mesenchymal markers in mouse ECs after lentiviral delivery of 
human MIR503HG followed by SuHx model of PH, suggests MIR503HG plays a key role in the prevention 
of EndMT. The overexpression of miR-424/503 in the lung has previously been shown to prevent and rescue 
the SuHx PH phenotype in rats42.  This suggests that MIR503HG and miR-424/503 may both contribute to 
pulmonary hypertension but probably through different processes, supporting a partner relationship 
between miRNAs and their host gene43. Further studies, including normoxic control mice and optimised 
delivery strategies, are required to address the effect of MIR503HG on the severity of the pulmonary 
hypertension phenotype. At present, the delivery of lncRNA to the EC compartment in vivo is too inefficient 
to justify such approaches. 
 
Taken together, our comprehensive analysis has provided important insights into EndMT and 
highlighted the critical functional role of the lncRNA MIR503HG. Our results open new avenues for 
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FIGURE LEGENDS 
 
Figure 1: EndMT in vitro model in venous EC.  
HUVEC were treated with TGF-β2 (10 ng/mL) and/or IL-1β (1 ng/mL) for 7 days. (A) Expression analysis 
of EndMT markers by RT-qPCR relative to UBC (relative quantification:RQ). (PECAM1 n=5, ACTA2, 
SNAI2 and COL1A1 n=8). Statistical analysis was done using a repeated measures one-way ANOVA with 
Bonferroni correction. (B) Representative images of immunofluorescence staining for PECAM1 (green), 
SNAI2 (red) and DAPI (blue) (scale bar 50 μm). (C) Quantification of EdU uptake in untreated and treated 
HUVECs (n=4) with representative FACS histogram plots. (D) Transwell migration assay of treated and 
untreated HUVECs with representative image of fixed migrated cells stained with DAPI (scale bar 100M) 
and quantification (n=3). Statistical analysis of panel C and D was done using linear mixed effects 
modelling.  
 
Figure 2: single-cell and bulk RNAseq analysis of EndMT identify a common lncRNA signature 
(A) tSNE plot of the 5 datasets (untreated HUVEC at day 0, 3 and 7 and TGF-β2 + IL-1β co-treated HUVEC 
at day3 and day7). (B) Violin and tSNE plots of endothelial and mesenchymal signature (C) Unsupervised 
cluster identification (D) Violin plot of endothelial (PECAM1, ICAM2), mesenchymal (TAGLN, COL1A1), 
EndMT (SNAI2) and proliferation (MKI67) marker expression (as z-score) in the different clusters. (E) 
Principal Component Analysis of control and EndMT-induced HUVEC and HPAEC (bulk RNAseq). (F) 
Overlap of EndMT up/down-regulated genes between HUVEC and HPAEC. (G) Heatmap of significantly 
regulated genes and (H) of candidate lncRNAs expression (as z-score). (I)  Violin plot of candidate lncRNA 
expression in the scRNA-seq clusters.  
 
Figure 3:  MIR503HG expression during EndMT in vitro.  
(A) Schematic representation of the MIR503HG, miRNA-424 and miRNA-503 loci based on GENCODE 
v26 annotation. (B) Expression of miRNA-424/-503 in HUVEC ± EndMT (TGF-β2 + IL-1β) (n=4) (C) 
MIR503HG_2 expression in HSVEC and HCAEC ± EndMT (n=3). (D) MIR503HG_2 expression in 




 (200nM) (n=3). (E) MIR503HG correlation to 
endothelial and mesenchymal signatures based on single-cell RNA-seq. (F) MIR503HG_2, 18S and NEAT1 
localisation by cell fractionation. (G) Mean MIR503HG nuclear copy number compared to unstained 
negative control (n=4) (H) and localisation of MIR503HG, SNORD3, and UBC by RNA-FISH in HUVEC. 
Relative quantification of RT-qPCR normalized to RNU48 or UBC relative to Control cells. Statistical 
analysis was done using linear mixed effects modelling for panel B and C or a repeated measures one-way 
ANOVA with Bonferroni correction for panel D.  
 
Figure 4: MIR503HG knockdown induces EndMT in HUVEC.  
 (A) MIR503HG_2 expression in siRNA-mediated MIR503HG depletion (si503HG) after 7 days in 
HUVEC (n=3) (B) EndMT marker gene expression in si503HG compared to control after 7 days (n= 3). 
(C) Representative immunofluorescence images of EndMT markers expression in HUVEC (scale bar 50 
μm) after knockdown using si503HG. PECAM1 (green), SNAI2 (red) and DAPI (blue). (D) MIR503HG_2 
(Left: CRISPR/Cas9-targeted Exon3 (Ex3), right: untargeted Exon1 (Ex1)), (E) miR-424 and miR-503, and 
(F) EndMT marker gene expression in HUVEC following CRISPR-mediated deletion of MIR503HG, using 
two lentiviral CRISPR/Cas9 gRNA pairs, after 8 days compared to empty control pairs (n=5).  Relative 
quantification of RT-qPCR normalised to RNU48 or UBC relative to Control cells.  Statistical analysis was 
done using linear mixed effects modelling for panel A and B and a repeated measures one-way ANOVA 
with Bonferroni correction for panel D-F.  
 
Figure 5: MIR503HG overexpression represses EndMT in vitro.  
Expression of (A) MIR503HG_2 and (B) EndMT marker genes in HUVEC following MIR503HG 




 http://ahajournals.org by on M
arch 15, 2021
 
DOI: 10.1161/CIRCRESAHA.120.318124   16 
for 7 days (n=5). Relative quantification of RT-qPCR normalized to UBC relative to LNT_CT in Control 
cells. Analysis by two-way ANOVA with Bonferroni correction. (C) Representative immunofluorescence 
images of EndMT markers in HUVEC following MIR503HG overexpression. PECAM1 (green), SNAI2 
(red) and DAPI (blue) (scale bar 50 μm). (D) Heatmap of the 1683 significant genes between LNT_503HG 
and LNT_CT in EndMT conditions (displayed as z-score). (E) Venn diagram of the overlap between 
significant changes due to MIR503HG overexpression in EndMT-cells (EndMT_LNT_503HG vs 
EndMT_LNT_CT) and EndMT changes (EndMT vs Control).  
 
Figure 6: MIR503HG modulation in mouse is associated with EndMT in PAH  
(A) Representative immunofluorescence staining of Normoxia/vehicle or SuHx mouse lung tissue for Cd31 
(green), Dapi (blue) and Acta2 or Snai2 (red) (scale bar 50 μm). (B) Endothelial and mesenchymal markers 
expression in TdTomato+ cells isolated from Normoxia/vehicle (n=8) or SuHx mouse lung tissue (n=7). (C) 
MIR503HG mouse lncRNA homolog Gm28730 expression in in TdTomato+ cells isolated from 
Normoxia/vehicle (n=8 mice) or SuHx mouse lung tissue (n=7). (D) Strategy to assess the effect of human 
MIR503HG_2 overexpression in EndMT in SuHx PAH model (E) Human MIR503HG_2, MIR503HG 
mouse lncRNA homolog Gm28730 and (F) Endothelial/mesenchymal marker expression in CD31+ lung 
cells isolated from SuHx mouse lung tissue following MIR503HG overexpression with LNT_503HG or 
LNT_Control (LNT_503HG n=5, LNT_Control n=4). Relative quantification of RT-qPCR normalized to 
18S relative to Normoxia (B-C) or LNT_CT (E-F). Statistical analysis of panel B and C was done using an 
unpaired two-tailed t-test except for Col1a1 expression, not following a normal distribution, analysed using 
a Mann-Whitney test. Panel E and F was analysed using Iman and Conover non-parametric ranking 
followed by unpaired two-tailed t-test.  
 
Figure 7: Human PAH is associated with loss of MIR503HG 
(A) MIR503HG_2 and EndMT markers gene expression in BOECs cells isolated from PAH patients and 
controls (control n=4, PAH n=5). Relative quantification of RT-qPCR normalized to UBC relative to 
Control cells. Analysis by Iman and Conover non-parametric ranking followed by unpaired two-tailed t-
test. (B) In situ hybridization for MIR503HG in control and PAH patient lungs, with brightfield staining, 
and pseudo fluorescence imaging to enhance visualisation of MIR503HG (purple/red) and the nucleus 
(pink/blue). (C) Immunofluorescence for smooth muscle cells (ACTA2, green), endothelial cells (vWF, 
red) and nucleus (DAPI, blue), and IgG controls in control and PAH patient lungs. Scale bar 50m. Dotted 
squares denote high-power view of vessels. 
 
Figure 8: MIR503HG binding partner PTBP1 regulates EndMT 
(A)  Schematic of MIR503HG in-vitro pulldown experiment. (B) Dot plot of -log10 pvalue versus log2 fold 
change of MIR503HG_2 interacting proteins compared to GFP control after RNA pulldown assay and mass 
spectrometry (n=3) (C) RT-qPCR analysis of MIR503HG_2 and UBC in RNA immunoprecipitation of IgG, 
PTBP1 and HNRNPA0 from HUVEC lysate (n=3). (D) Western blot analysis of PTBP1 level in si503HG 
in HUVEC after 7 days. GAPDH used as a loading control. (E) Western blot analysis of PTBP1 level in 
CONTROL and EndMT HUVEC. GAPDH used as a loading control (F) EndMT marker expression in 
siPTBP1 samples 7 days after transfection (n=5). (G) Overlap of genes significantly down-regulated by 
LNT_503 in EndMT condition, up-regulated in EndMT compared to control and up-regulated by PTBP1 
in HepG2 cells. Relative quantification of RT-qPCR normalized to UBC relative to siCONTROL treatment. 
Statistical analysis was done using a repeated measures one-way ANOVA with Bonferroni correction for 
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NOVELTY AND SIGNIFICANCE 
 
What Is Known? 
 
 Endothelial to mesenchymal transition (EndMT) is a complex process contributing to vessel 
remodeling during disease, including Pulmonary Arterial Hypertension (PAH). 
 
 Long non-coding RNAs (lncRNAs) regulate many biological processes and are involved in 
vascular biology and disease. 
 
 
What New Information Does This Article Contribute? 
 
 Transcriptomic changes associated with EndMT include lncRNAs. 
 
 The lncRNA MIR503HG is downregulated during EndMT in vitro, as well as in mouse and human 
PAH samples. 
 
 Down-regulation of MIR503HG level induces a spontaneous EndMT profile which may be 
mediated, in part, by MIR503HG interaction with the RNA binding protein PTBP1. 
 
EndMT transition occurs during development and pathological vessel remodeling. Regulators of 
EndMT are still poorly characterized. LncRNAs are key regulators of many biological processes and 
involved in disease. Here, we identify lncRNAs regulated during EndMT and show that the lncRNA 
MIR503HG expression is decreased during EndMT in vitro. Loss of MIR503HG was also observed 
both in mouse and human PAH samples. Down-regulation of MIR503HG alone recapitulates EndMT 
while its overexpression reduces EndMT. MIR503HG mechanism of action was uncovered, by 
identifying the RNA binding protein PTBP1 as a binding partner and showing PTBP1 regulation of 
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